Business description: Zoetis Inc.

Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows:

- companion animal (67.8%): cats and dogs (95.5% of net sales) and horses (4.5%);

- livestock (31.3%): cattle (52.8% of sales), poultry (18.2%), swine (17.8%), fish (8.4%) and other (2.8%);

- other (0.9%).

Net sales break down by family of products into parasiticides (23.3%), vaccines (19.7%), dermatological products (17.9%), anti-infectives (11.9%), pain relievers (9.2%), diagnostic products (4.2%), medicated feed additives (3.2%) and other (10.6%).

At the end of 2024, the group has 22 production sites worldwide.

The United States accounts for 54.8% of net sales.

Number of employees: 14,500

Sales by Activity: Zoetis Inc.

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

United States (U.S.)

404.2Cr 431.3Cr 455.5Cr 507.4Cr 509.7Cr

International

365.2Cr 368.1Cr 391.1Cr 410.2Cr 425.4Cr

Unallocated Contract Manufacturing & Human Health

8.2Cr 8.6Cr 7.8Cr 8Cr 12Cr

Geographical breakdown of sales: Zoetis Inc.

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

United States (U.S.)

404.2Cr 431.3Cr 455.5Cr 507.4Cr 509.7Cr

Other Emerging Markets

78Cr 76Cr 78Cr 86Cr 91Cr

Other Developed Markets

47Cr 47Cr 51Cr 56Cr 64Cr

Brazil

31Cr 33Cr 39Cr 41Cr 39Cr

Australia

26Cr 29Cr 32Cr 32Cr 33Cr

United Kingdom

23Cr 24Cr 28Cr 31Cr 32Cr

Canada

23Cr 24Cr 26Cr 28Cr 29Cr

Germany

18Cr 18Cr 20Cr 22Cr 24Cr

China

36Cr 38Cr 32Cr 27Cr 23Cr

France

13Cr 13Cr 14Cr 16Cr 16Cr

Mexico

13Cr 14Cr 16Cr 17Cr 16Cr

Japan

19Cr 17Cr 16Cr 15Cr 15Cr

Spain

13Cr 12Cr 12Cr 13Cr 14Cr

Chile

14Cr 14Cr 14Cr 12Cr 14Cr

Italy

12Cr 11Cr 12Cr 13Cr 14Cr

Unallocated

8.2Cr 8.6Cr 7.8Cr 8Cr 12Cr

Executive Committee: Zoetis Inc.

Manager TitleAgeSince
Chief Executive Officer 54 01/01/2020
Director of Finance/CFO 54 01/06/2021
Chief Tech/Sci/R&D Officer 49 01/01/2026
Chief Operating Officer 53 01/08/2024
Chief Tech/Sci/R&D Officer - 21/03/2024

Composition of the Board of Directors: Zoetis Inc.

Director TitleAgeSince
Director/Board Member 68 01/07/2012
Director/Board Member 68 01/01/2013
Chairman 73 26/06/2013
Director/Board Member 73 01/06/2013
Director/Board Member 71 04/03/2014
Director/Board Member 65 01/05/2015
Director/Board Member 54 02/10/2019
Director/Board Member 64 08/12/2020
Director/Board Member 57 25/07/2022
Director/Board Member 63 01/04/2024

Shareholders: Zoetis Inc.

NameStocks%Valuation
BlackRock Advisors LLC
6.394 %
2,68,06,560 6.394 % 1 926 M $
Vanguard Capital Management LLC
6.219 %
2,60,72,846 6.219 % 1 874 M $
Vanguard Portfolio Management LLC
5.717 %
2,39,67,400 5.717 % 1 722 M $
4.61 %
1,93,24,401 4.61 % 1 389 M $
State Farm Investment Management Corp.
3.791 %
1,58,92,903 3.791 % 1 142 M $

Company details: Zoetis Inc.

Zoetis, Inc.

10 Sylvan Way

07054, Parsippany

+973 822 7000

http://www.zoetis.com
address Zoetis Inc.(ZTS)

Group companies: Zoetis Inc.

NameCategory and Sector
Zoetis Treasury Center BV
Biotechnology
Pharmaceuticals: Major
Zoetis Philippines, Inc.
Pharmaq Vietnam Co. Ltd.

Veterinary Drugs

Change 5-day change 1-year change 3-year change Capi.($)
+3.19%+2.44%-49.25%-55.33% 3.22TCr
+1.61%+5.40%+78.84%+119.17% 1.3TCr
+4.18%+4.85%-15.35%+2.49% 373.73Cr
0.00%+1.87%-8.03%+31.12% 312.93Cr
-1.56%-1.31%+38.80%+26.00% 193.9Cr
+1.84%+8.54%-23.50%+26.15% 178.7Cr
+2.31%+6.61%+13.03%+136.76% 140.03Cr
+0.92%+7.24%-23.50%-11.04% 110.2Cr
+1.84%+10.48%-15.41%-43.87% 100.1Cr
+0.41%+2.82%-8.86%-17.70% 97Cr
Average +1.09%+4.38%-1.32%+21.37% 602.66Cr
Weighted average by Cap. +0.37%+3.48%-10.73%+1.37%
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
76.91USD
Average target price
114.76USD
Spread / Average Target
+49.22%

Quarterly revenue - Rate of surprise